CT-1119
Mesothelin-expressing solid tumors
Pre-clinicalActive
Key Facts
Indication
Mesothelin-expressing solid tumors
Phase
Pre-clinical
Status
Active
Company
About Carisma Therapeutics
Carisma Therapeutics is focused on developing a new class of immunotherapies by engineering macrophages, which are innate immune cells capable of infiltrating solid tumors and modulating the tumor microenvironment. The company's lead candidate, CT-0508, is in Phase 1 clinical trials for HER2-overexpressing solid tumors, representing a first-in-class approach. Carisma has established strategic collaborations with industry leaders like Moderna and Sesen Bio to expand its platform and pipeline. Despite being a clinical-stage company with no approved products, it has attracted significant investment and attention for its innovative technology.
View full company profile